The German coalition government has agreed to consider "constructive recommendations" put forward by experts at parliamentary health committee hearings on the government's third-stage health reform proposals, Health Minister Horst Seehofer has said.
The rethink will include consideration of what control individual health funds will have over patient charges imposed for medicines. The government plan would assign responsibility for management of the charges to each fund, but the plan has met opposition from drug companies producing either "controversial" or over-the-counter drugs, who fear the funds will load the patient charges in this area.
The public-sector funds recorded a deficit of 8.7 billion Deutschemarks ($5.7 billion) in the first nine months of 1996, said Mr Seehofer. During 1991-95, spending by the funds rose 32% to 229 billion marks overall, while gross salaries and wages of insured people rose only 15%. The funds spent 6.1 billion marks more on health care in the first nine months of 1996 than in the same period of 1995; government supporters say this proves the health service is by no means being ruined by economies, and that spending has to be reduced to what is medically necessary.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze